generic namzaric availability  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › generic drugs › namzaric print share generic namzaric availability namzaric is a brand name of donepezilmemantine approved by the fda in the following formulations namzaric donepezil hydrochloride memantine hydrochloride  capsule extended releaseoral manufacturer forest labs llc approval date december   strengths mgmg ab mgmg rld ab manufacturer forest labs llc approval date july   strengths mgmg mgmg has a generic version of namzaric been approved a generic version of namzaric has been approved by the fda however this does not mean that the product will necessarily be commercially available  possibly because of drug patents andor drug exclusivity the following products are equivalent to namzaric and have been approved by the fda memantine hydrochloride and donepezil hydrochloride donepezil hydrochloride memantine hydrochloride capsule extended releaseoral manufacturer amneal pharms approval date january   strengths mgmg ab mgmg ab note fraudulent online pharmacies may attempt to sell an illegal generic version of namzaric these medications may be counterfeit and potentially unsafe if you purchase medications online be sure you are buying from a reputable and valid online pharmacy ask your health care provider for advice if you are unsure about the online purchase of any medicationsee also about generic drugs related patents patents are granted by the us patent and trademark office at any time during a drugs development and may include a wide range of claims modified release formulations of memantine oral dosage formspatent issued october  inventors rastogi suneel k  rao niranjan  periclou antonia  abramowitz wattanaporn  dedhiya mahendra g  mahashabde shashankassignees forest laboratories holdings limitedthe present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine and a pharmaceutically acceptable polymeric matrix carrier the dosage forms of the invention sustain the release of the therapeutically active agent from about  to about  hours when said dosage form is exposed to aqueous solutions following entry of said form into a use environment wherein said dosage form has a dissolution rate of more than about  after passage of about  hours to about  hours following said entry into said use environmentpatent expiration dates march  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type september  ✓ pediatric exclusivity methods and compositions for the treatment of cnsrelated conditionspatent issued november  inventors went gregory t  fultz timothy jassignees adamas pharmaceuticals incthe present invention provides novel methods and compositions for the treatment and prevention of cnsrelated conditions one of the cnsrelated conditions treated by the methods and compositions of the invention is alzheimers diseasepatent expiration dates december  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type method and composition for administering an nmda receptor antagonist to a subjectpatent issued may  inventors went gregory t  fultz timothy j  porter seth  meyerson laurence r  burkoth timothy sassignees adamas pharmaceuticals incthe invention provides methods and compositions for administering an nmda receptor antagonist eg memantine to a subjectpatent expiration dates november  ✓ drug product may  ✓ pediatric exclusivity method and composition for administering an nmda receptor antagonist to a subjectpatent issued may  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe invention provides methods and compositions for administering an nmda receptor antagonist eg memantine to a subjectpatent expiration dates november  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type may  ✓ pediatric exclusivity methods and compositions for the treatment of cnsrelated conditionspatent issued october  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe present invention provides novel methods and compositions for the treatment and prevention of cnsrelated conditions one of the cnsrelated conditions treated by the methods and compositions of the invention is alzheimers diseasepatent expiration dates november  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type may  ✓ pediatric exclusivity methods and compositions for the treatment of cnsrelated conditionspatent issued october  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe present invention provides novel methods and compositions for the treatment and prevention of cnsrelated conditions one of the cnsrelated conditions treated by the methods and compositions of the invention is alzheimers diseasepatent expiration dates november  ✓ drug product composition for administering an nmda receptor antagonist to a subjectpatent issued december  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe invention provides compostions for administering memantine to a subject memantine in an extended release form containing  to  mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentrationpatent expiration dates november  ✓ drug product may  ✓ pediatric exclusivity compositions for the treatment of cnsrelated conditionspatent issued december  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject memantine in an extended release form containing  to  mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentrationpatent expiration dates november  ✓ drug product methods for the treatment of cnsrelated conditionspatent issued december  inventors went gregory t  fultz timothy j  meyerson laurence rassignees adamas pharmaceuticals incthe invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject memantine in an extended release form containing  to  mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition such as alzheimers disease parkinsons disease or dementia the extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentrationpatent expiration dates november  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type method for administering an nmda receptor antagonist to a subjectpatent issued january  assignees adamas pharmaceuticals incthe invention provides methods for administering memantine to a subject memantine in an extended release form containing  to  mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition such as alzheimers disease parkinsons disease or dementia the extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentrationpatent expiration dates november  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type may  ✓ pediatric exclusivity compositions for the treatment of cnsrelated conditionspatent issued november  assignees adamas pharmaceuticals incthe invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject memantine in an extended release form containing  to  mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentrationpatent expiration dates november  ✓ patent use memantine hcldonepezil hcl combination for the treatment of moderate to severe dementia of the alzheimers type method for administering an nmda receptor antagonist to a subjectpatent issued december  assignees adamas pharmacueticals inccompositions and methods for administering memantine to a subject are provided in particular a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided the compositions comprises an extended release formulation of  mg to  mg memantine or a pharmaceutically acceptable salt thereof wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time dcdt that is less than  of the dcdt provided by the same quantity of an immediate release form of memantine determined in a time period between  hours to  hours after administration of memantine and wherein dcdt is measured in a singledose human pk study methods of treating dementia in particular alzheimers diseases using the compositions are providedpatent expiration dates november  ✓ drug product may  ✓ pediatric exclusivity share on googleplus share on facebook share on twitter print this page email to a friend add to my med list more about namzaric donepezil  memantine side effects during pregnancy dosage information drug images drug interactions support group pricing  coupons en español  reviews – add your own reviewrating generic availability drug class cholinesterase inhibitors consumer resources namzaric namzaric advanced reading professional resources namzaric fda related treatment guides alzheimers disease glossary termdefinition drug patenta drug patent is assigned by the us patent and trademark office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation the patent assigns exclusive legal right to the inventor or patent holder and may include entities such as the drug brand name trademark product dosage form ingredient formulation or manufacturing process a patent usually expires  years from the date of filing but can be variable based on many factors including development of new formulations of the original chemical and patent infringement litigation drug exclusivityexclusivity is the sole marketing rights granted by the fda to a manufacturer upon the approval of a drug and may run simultaneously with a patent exclusivity periods can run from  days to seven years depending upon the circumstance of the exclusivity grant rlda reference listed drug rld is an approved drug product to which new generic versions are compared to show that they are bioequivalent a drug company seeking approval to market a generic equivalent must refer to the reference listed drug in its abbreviated new drug application anda by designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent fda hopes to avoid possible significant variations among generic drugs and their brand name counterpart abproducts meeting necessary bioequivalence requirements multisource drug products listed under the same heading ie identical active ingredientss dosage form and routes of administration and having the same strength see therapeutic equivalencerelated terms pharmaceutical equivalents generally will be coded ab if a study is submitted demonstrating bioequivalence in certain instances a number is added to the end of the ab code to make a three character code ie ab ab ab etc threecharacter codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other if a study is submitted that demonstrates bioequivalence to a specific listed drug product the generic product will be given the same threecharacter code as the reference listed drug it was compared against drug status availability rx prescription only pregnancy category c risk cannot be ruled out csa schedule n not a controlled drug approval history calendar drug history at fda close namzaric rating no reviews  be the first no reviews  be the first not rated  be the first manufacturer forest laboratories inc drug class cholinesterase inhibitors recently approved vosevi vosevi sofosbuvir velpatasvir and voxilaprevir or sof  vel  vox is a fixeddose combination of a nerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of tremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of moderatetosevere endari endari lglutamine is orallyadministered pharmaceutical grade lglutamine pglg an amino acid more fda consumer updates depression fdaapproved medications may help dealing with adhd what you need to know making decisions for your health getting the info you need fda cuttingedge technology sheds light on antibiotic resistance more fda updates namzaric images namzaric donepezil hydrochloride  mg  memantine hydrochloride  mg fl  view larger images related news and articles noninvasive brain test may pinpoint type of dementia july   teaching an old brain new tricks july   targeting  risk factors could prevent  in  dementia cases study july   drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide gregory t went  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors gregory t went check out list of companies and businesses related to gregory t went find out gregory t went address and contact details view other people related to gregory t went  coworkers colleagues companions etc address co adamas pharmaceuticals inc  powell st ste  emeryville  ca companies related to gregory t went cikcompany namepositioncompany addressadamas pharmaceuticals incchief executive officer  powell st suite  emeryville  gregory t went on the web persons related to gregory t went  adamas pharmaceuticals incnamepositioncityaeris capital equity investments lp owner grand caymanaeris capital equity investments lp owner grand caymanmichael bighamdirector menlo parkrichard h boothdirector berlinrichard h boothdirector emeryvillerichard h boothdirector emeryvillejohn j cadeddupalo altomichael denis coffeeemeryvilledag ventures gp fund iii llcpalo altodag ventures iii lppalo altodag ventures iiiqp lppalo altodag ventures management iii llc owner palo altowilliam j dawsonchief financial officer berkeleywilliam j dawsonemeryvillemartha j demskidirector san diegomartha j demskiemeryvillewilliam w ericsondirector menlo parkwilliam w ericsondirector menlo parkjonathan d feibermenlo parkjonathan d feibermenlo parkjonathan d feibermenlo parkr thomas goodrichpalo altogreat point partners llc owner greenwichsara l grootwassinkdirector rockvillejeffrey r jaygreenwichrichard kingchief operating officer miamijeffrey h knappchief operating officer fremontjeffrey h knappemeryvilledavid kroindanburysara grootwassink lewisemeryvilleivan m lieberburgdirector los angelesivan m lieberburgemeryvilleivan m lieberburgdirector emeryvillejohn a macpheedirector woodcliff lakejohn a macpheeemeryvilledavid l mahoneydirector cupertinodavid l mahoneyemeryvillenatalie mccluresvp product development emeryvillenatalie mccluresvp product development emeryvillemdv enf vii a lpmenlo parkmdv enf vii b lpmenlo parkmdv ix lp owner menlo parkmdv ix lpmenlo parkmdv ix lpmenlo parkmdv vii leaders fund lpmenlo parkmdv vii lpmenlo parkmdv vii lpmenlo parkmdv vii lp owner menlo parkalfred g merriweatherchief financial officer mountain viewninth mdv partners llcmenlo parkninth mdv partners llcmenlo parkninth mdv partners llcmenlo parkrajiv patnichief medical officer palo altojennifer j rhodescbo gc  compliance officer san franciscoanthony m rimacemeryvillenancy j schoendorfnancy j schoendorfmenlo parknancy j schoendorfmenlo parkseventh mdv partners llcmenlo parkseventh mdv partners llcmenlo parkseventh mdv partners llcmenlo parkgrace shingeneral counsel emeryvillegregory t wentchief executive officer emeryville insider trading  went gregory t  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  went gregory t select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view sale  pm adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner    indirectdirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing other  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   direct view other  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   indirect view other  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   direct view other  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   direct view other  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   direct view other  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view option award  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view option award  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm nana adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view exercise  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view option award  pm na adamas pharmaceuticals inc adms went gregory tchief executive officerdirector owner   direct view   secformcom all rights reserved archives        sat  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  gregory went adamas pharmaceuticals inc profile  biography  bloomberg feedback gregory went chairmanceocofounder adamas pharmaceuticals inc career history chairmanceocofounder adamas pharmaceuticals inc present cofounder tethys bioscience inc present managing director halteres associates present cofounder curagen corp present chief operating officer dna sciences inc  coo kiva genetics inc  exec vpcofounder curagen corp unknown show more website wwwadamaspharmacom corporate information address  powell street suite  emeryville ca  united states phone  fax  web url wwwadamaspharmacom from the web personal information education university of california irvine phd carnegie learning bachelors degree memberships board memberships tethys bioscience inc board member present angelica therapeutics inc board member present adamas pharmaceuticals inc chairman present dna sciences inc board member  kiva genetics inc board member  curagen corp board member  show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data gregory t went phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in gregory t went phd co founder chief executive officer and chairman of the board at adamas pharmaceuticals inc view full profile are you gregory t went phd claim your profile   sign up for equilar atlas and view gregory t went phds full profile with equilar atlas you can identify corporate executives in gregory t went phds network and community follow changes in gregory t went phds employment and moneyinmotion connect with gregory t went phd through your network of contacts gregory t went phds executive work history current co founder chief executive officer and chairman of the board adamas pharmaceuticals inc past to view gregory t went phds complete executive work history sign up now age      gregory t went phds biography dr went age  has served as our chief executive officer and chairman of our board of directors since our inception in  previously dr went cofounded curagen corporation in  where he served as an executive vice president and director from  to  dr went also has served as a director of angelica therapeutics inc a biotechnology company since  dr went holds a phd in chemical engineering from the university of california berkeley and a bs in chemical engineering from carnegie mellon university we believe dr wents extensive knowledge of our company the pharmaceutical industry and our competitors qualifie  read more dr went age  has served as our chief executive officer and chairman of our board of directors since our inception in  previously dr went cofounded curagen corporation in  where he served as an executive vice president and director from  to  dr went also has served as a director of angelica therapeutics inc a biotechnology company since  dr went holds a phd in chemical engineering from the university of california berkeley and a bs in chemical engineering from carnegie mellon university we believe dr wents extensive knowledge of our company the pharmaceutical industry and our competitors qualifies him to serve on our board of directors source adamas pharmaceuticals inc on    sign up for equilar atlas and view gregory t went phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like gregory t went phd more specifically youll be able to identify corporate executives in gregory t went phds network and community follow changes in gregory t went phds employment and moneyinmotion connect with gregory t went phd through your network of conections view full profile   search for over  executive profiles bio example gregory t went phd gregory t went phds connections  sign up now to view gregory t went phds  connections » david l mahoney board member symantec corporation william w ericson lead independent director pacific biosciences of california inc natalie mcclure former senior vice president product development adamas pharmaceuticals inc jennifer j rhodes general counsel corporate secretary and chief compliance officer adamas pharmaceuticals inc richard h booth former board member the hanover insurance group inc sara g lewis board member ps business parks inc martha j demski board member chimerix inc jeffrey h knapp chief operating officer aimmune therapeutics inc rajiv patni chief medical officer adamas pharmaceuticals inc anthony rimac former consultant adamas pharmaceuticals inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   gregory t went  cantor fitzgerald  internet conference overviewregistrationinvestorscorporatesotherparticipating companiesschedule  agendageneral informationquestions  contact gregory t went chairman  ceo dr went founding ceo and chairman of adamas pharmaceuticals has overseen the development of the company since its inception previously dr went cofounded curagen corporation in  where he served as an executive vice president and director dr went received his phd in chemical engineering from the university of california berkeley and a bs in chemical engineering from carnegie mellon university dr went is the author of  papers and an inventor on more than  issued patents and pending applications adamas pharmaceuticals adamas pharmaceuticals inc nasdaq adms is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system the company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixeddose combination products adamas is currently developing its lead whollyowned product candidate ads for a complication associated with the treatment of parkinsons disease known as levodopainduced dyskinesia or lid and is evaluating other potential indications including for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment the companys portfolio also includes two approved products with forest laboratories holdings limited a subsidiary of allergan plc namzaric™ and namenda xr® forest is responsible for marketing both products in the united states under an exclusive license from adamas for more information please visit wwwadamaspharmacom copyright   cantor fitzgerald all rights reserved privacy statementdisclaimer went gregory t  current holdings  fintelio went gregory t current holdings from f d investorwent gregory t current positions went gregory t has disclosed  total holdings in their latest sec filings this investor has not filed a f which indicates it has under m in assets under management aum went gregory t s top industries are chemicals and allied products sic   overview sec filings dg predictive value all went gregory t holdings are listed in the following table this data is sourced from dg and f filings green rows indicate new positions red rows indicate closed positions add this fundto your dashboard this is a list of d and g filings made since the last quarterly f report if any file dateformsecurity prevshares currentshares changepercent prev valuex current valuex changepercent ‑‑ sc ga adms  adamas pharmaceuticals inc     fintel ir  find the right investors for your company instantly fintel ir combines the comprehensive fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy learn more now from the blog how to launch a hedge fund the piotroski score adamas pharmaceuticals  executive management adamas contact home executive management members of our executive management have played leading roles in the development and commercialization of multiple significant drugs in a wide range of therapeutic areas gregory t went phd chief executive officer  chairman dr went founding ceo and chairman of adamas pharmaceuticals has overseen the development of the company since its inception previously dr went cofounded curagen corporation in  where he served as an executive vice president and director dr went received his phd in chemical engineering from the university of california berkeley and a bs in chemical engineering from carnegie mellon university dr went is the author of  papers and an inventor on more than  issued patents and pending applications alfred g merriweather chief financial officer mr merriweather joined the company in june  before coming to adamas he was chief financial officer at raindance technologies inc prior to raindance he served as chief financial officer of verinata health inc and before that as chief financial officer of celera corporation mr merriweather previously spent over  years in senior financial positions at several private and public life science companies including monogram biosciences inc and laserscope mr merriweather received a bachelor’s degree from the university of cambridge in the united kingdom richard a king chief operating officer mr king joined the company in april  before coming to adamas mr king was chief operating officer at the scripps research institute he previously served as president and ceo of acelrx pharmaceuticals inc a specialty pharmaceutical company developing new pain medications prior to acelrx he was president chief operating officer and general manager of the biotechnology company tercica inc later sold to the ipsen group where he was instrumental in the commercial launch of dysport® abobotulinumtoxina and increlex™ rhlgf he also previously served as executive vice president of commercial operations at kos pharmaceuticals inc where he oversaw the growth of niaspan® niacin extendedrelease and the launch of advicor® niacin extendedreleaselovastatin he was senior vice president of commercial operations at solvay and vice president of commercial operations at unimed where he launched androgel® testosterone gel mr king received a bsc in chemical engineering from the university of surrey in the uk and an mba from the manchester business school in the uk rajiv patni md chief medical officer dr patni joined adamas as chief medical officer in june  dr patni brings over  years of global drug development experience across multiple therapeutic areas as well as extensive knowledge of the drug approval process prior to joining adamas dr patni served as chief development officer at ocera therapeutics earlier in his career he served as svp chief medical officer at actelion us pharmaceuticals executive directorvp product lifecycle team leader therapeutic area head at roche pharmaceuticals and senior medical director development team leader at novartis and pfizer pharmaceuticals dr patni earned a bs from the city university of new york sophie davis school of biomedical education accelerated bsmd program and an md from the mount sinai school of medicine he completed his residency and fellowship in internal medicine and cardiology at the albert einstein college of medicine in new york where he was also an attending physician jennifer j rhodes chief business officer general counsel chief compliance officer and corporate secretary ms rhodes joined as our general counsel and corporate secretary in april  she previously served as general counsel at medivation inc where she was responsible for medivation’s legal matters and also served as corporate secretary and as chief compliance officer before medivation ms rhodes was an assistant general counsel at pfizer inc where she supported the us primary care business and its primary care medicines development group and served as a global product lead for pfizer inc’s primary care medicines prior to joining pfizer ms rhodes was an associate in the regulatory law and international trade practice areas at weil gotshal  manges llp she also served as a law clerk for chief judge gregory a carman on the united states court of international trade ms rhodes received a jd from wake forest university school of law and a ba in economics from newcomb college of tulane university adms gregory t went insider trades for adamas pharmaceuticals inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close adamas pharmaceuticals inc nasdaq adms go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus adamas pharmaceuticals inc after hours  quotes are delayed by  min jul    pm adms quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual gregory t went dr gregory t went is chairman  chief executive officer at adamas pharmaceuticals inc and a managing director at halteres associates llc he is on the board of directors at angelica therapeutics inc dr went was previously employed as chairman  chief executive officer by neuromolecular pharmaceuticals inc director  executive vice president by curagen corp and an advisor by presidio partners he also served on the board at tethys bioscience inc and parallele bioscience inc he received his undergraduate degree from carnegie mellon university and a doctorate degree from the university of california berkeley transactions date shares transaction value     disposition at  per share      award at  per share                derivativenonderivative trans at  per share      award at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share           derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr gregory t went chairman  chief executive officer mr richard a king chief operating officer mr alfred g merriweather chief financial officer dr rajiv patni chief medical officer ms jennifer j rhodes secretary chief compliance  business officer mr michael denis coffee senior vice presidentstrategy  planning dr natalie l mcclure senior vice presidentproduct development mr john a macphee director mr michael f bigham director ms ashleigh barreto directorcommunications  investor relations ms leonie mcconville senior vice presidenthuman resources ms martha j demski independent director mr richard h booth independent director mr david l mahoney lead independent director dr ivan m lieberburg independent director mr william w ericson independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice